Almirall To Position Oral DMF For Psoriasis Ahead Of EU Biologics Use
Executive Summary
Almirall aims to start selling its unpatented fumaric acid derivative throughout Europe in the third quarter for treating plaque psoriasis, but will not seek approval for the medicine in the US.
You may also be interested in...
Interview: Almirall CEO Guenter Plots 'Play To Win' Future
Peter Guenter has steadied the ship at Almirall, and after seven months in the role he outlines his vision for the company in his first exclusive interview as CEO of Spain's largest pharma company.
Almirall To Put More Skin In The Game With Derma Buys
The Spanish company has a lot riding on tildrakizumab, the psoriasis drug licensed from Sun Pharma which could get the green light in Europe before year-end. Until then, Almirall is scouring the market for bolt-on deals.
Almirall's "Perfect Storm": How Will It Recover?
Changes in business processes in the US, and the launch of new products including a competitively priced Skilarence in the EU, are expected to help Almirall recover from setbacks over the coming months.